Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial

Abstract

Diabetes and hyperinsulinemia may be risk factors for Alzheimer's disease (AD). We conducted a pilot study of metformin, a medication efficacious in treating and preventing diabetes while reducing hyperinsulinemia, among persons with amnestic mild cognitive impairment (AMCI) with the goal of collecting preliminary data on feasiblity, safety, and efficacy. Participants were 80 men and women aged 55 to 90 years with AMCI, overweight or obese, without treated diabetes. We randomized participants to metformin 1000 mg twice a day or matching placebo for 12 months. The co-primary clinical outcomes were changes from baseline to 12 months in total recall of the Selective Reminding Test (SRT) and the score of the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). The secondary outcome was change in relative glucose uptake (rCMRgl) in the posterior cingulate-precuneus in brain Fluorodeoxyglucose Positron Emission Tomography. Change in plasma Aβ42 was an exploratory outcome. The mean age of participants was 65 years. Fifty % of participants were women. The only baseline variable that was different between the arms was the ADAS-Cog. Metformin could not be tolerated by 7.5% of participants; 15% tolerated 500 mg/day, 35% tolerated 1000 mg/day, 32.5% tolerated 1500 mg/day, and only 10% tolerated the maximum dose. There were no serious adverse events related to metformin. The 7.5% of persons who did not tolerate metformin reported gastrointestinal symptoms. After adjusting for baseline ADAS-cog, changes in total recall of the SRT favored the metformin group (9.7 ± 8.5 vs. 5.3 ± 8.5; p = 0.02). Differences for other outcomes were not significant. A larger trial seems warranted to evaluate the efficacy and cognitive safety of metformin in prodromal AD.

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums

“…For instance, investigators have begun testing of metformin, the most commonly prescribed drug for T2DM, in nondiabetic individuals with MCI or early dementia due to AD, with some signs of benefit 275,276 . In addition, thiazolidinedione-based nuclear peroxisome proliferator-activated receptor-γ (PPARγ) agonists, which were originally developed as insulin sensitizers for T2DM, have shown numerous beneficial neural effects in animal models of neurodegenerative diseases 277 .…”

A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies

“…A small pilot study investigating the effects of metformin treatment in patients with amnestic mild cognitive impairment at risk for developing type II diabetes reports an improvement in one, but not all, measures of cognition [59]. A larger study investigating the effects of lifestyle intervention and metformin on brain glucose metabolism and cognition is currently in phase 4 clinical trials (NCT02409238).…”

Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer’s Disease

“…The confounding factor in the Australian study was that the adverse effects of metformin were largely due to concomitant Vitamin B12 deficiencies, which when corrected, abrogated the apparently detrimental effects of metformin. In a later independent study, metformin treatment of overweight or obese, previously untreated diabetics with amnestic mild cognitive impairment had a statistical trend for positive performance effects on the selective reminding test [239]. Given the widespread use of metformin and its potential effects on cognition, additional research including execution of a large multinational longitudinal study and meta-analysis of smaller studies are warranted.…”